Citations

Clear

861 citation(s) found for "Sd, Wexner".

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
Kaumaya, Pravin T. P. , Guo, Linlin , Overholser, Jay , Penichet, Manuel L. , Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S

Mayo Clinic

OncoImmunology | October 1, 2020 | Volume: 9 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1818437 | PMID 33117602 Get It

The American College of Surgeons Response to the COVID-19 Pandemic (Part I): Cancer Care, COVID-19 Registry, Surgeon Wellness
Wexner, Steven D. , Nelson, Heidi , Stain, Steven C. , Turner, Patricia L. , Cortés‐Guiral, Delia , Wexner, Steven D

Mayo Clinic

The American Surgeon™ | September 11, 2020 | Volume: 86 | Issue: 7 | Pages: 751-756

10.1177/0003134820940771 | PMID 32916067 Get It

From the onset of the COVID-19 global pandemic of 2020, the American College of Surgeons has been a leader in disseminating reliable information on the nature of the crisis and assuring quality of surgical care during the enforced lockdown of inpatient and outpatient care.
The NEALS primary lateral sclerosis registry
Chan, James , Thrower, Sara, Staff, Nathan P. , Datta, Neil, Kisanuki, Yaz Y. , Drory, Vivian E., Fournier, Christina , Goutman, Stephen A. , Atassi, Nazem , Group, On behalf of the NEALS PLS Registry Study, Jeon, Maryangel, Caldwell, Sarah, McDonough, Timothy, Gentile, Caroline, Liu, Jianing , Turner, M.F., Denny, Carol, Felice, Kevin J. , Green, Misty, Scarberry, Stephanie, Abu-Saleh, Saad, Nefussy, Beatrice, Hastings, Debbie, Kim, S. K., Swihart, Blake, Arcila-Londono, Ximena , Newman, Daniel S. , Silverman, Michael G. , Genge, Angela , Salmon, Kristiana , Elman, Lauren , McCluskey, Leo, Almasy, Kelly, Goslin, Kimberly, CUMMINGS, A. J., Edwards, Eli K., Rivner, Michael H. , Bouchard, Kristy, Quarles, Brandy, Kwan, Justin , Jaffa, Matthew , Baloh, Robert H. , Allred, Peggy, Walk, David , Maiser, Samuel, Manousakis, Georgios , Ferment, Valerie, Fernandes, J. Americo, Thaisetthawatkul, Pariwat , Heimes, Deborah, Sams, Laura, Kahler, Melissa, Corcoran, Alecia, Larriviere, Daniel G., Chotto, Sadie, Juba, Gracy, Staff, Nathan P , Turner, Michelle, Goutman, Stephen A , Walk, David , Paganoni, Sabrina , Marchi, Fabiola De , Pioro, Erik P. , Group, On behalf of the NEALS PLS Registry Study, Caldwell, Sarah, Mcdonough, Timothy, Turner, Michelle, Denny, C. Dimla, Newman, Daniel S., Silverman, Michael, Gotkine, Marc , Cummings, Arlena, Phillips, Melissa

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | September 11, 2020 | Volume: 21 | Issue: sup1 | Pages: 74-81

10.1080/21678421.2020.1804591 | PMID 32915077 Get It

Maximal Medical Improvement following Shoulder Stabilization Surgery May Require up to 1 Year: A Systematic Review
Patel, Bhavik H. , Agarwalla, Avinesh , Puzzitiello, Richard N. , Nwachukwu, Benedict U. , Cvetanovich, Gregory L. , Forsythe, Brian, Lu, Yining , Chahla, Jorge , Forsythe, Brian

Mayo Clinic

HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery | September 10, 2020 | Volume: 16 | Issue: 2_suppl | Pages: 534-543

10.1007/s11420-020-09773-5 | PMID 33380993 Get It

Background There is increased emphasis on properly allocating healthcare resources to optimize value within orthopedic surgery. Establishing time to maximal medical improvement (MMI) can inform clinical decision-making and practice guidelines. Purpose We sought (1) to evaluate the time to MMI as predicted by commonly used patient-reported outcome measures (PROMs) for evaluation of shoulder stabilization and (2) to evaluate typical time to return to sports and employment following surgery. Methods A systematic review of the Medline database was conducted to identify outcome studies reporting sequential follow-up at multiple time points, up to a minimum of 2 years after shoulder stabilization surgery. The included studies examined the outcomes of arthroscopic or open surgical techniques on anterior instability. Clinically significant improvements were evaluated utilizing the minimal clinically important difference specific to each PROM. Secondary outcomes included range of motion, return to sport/work, and recurrent instability. Results Ten studies comprising 590 surgically managed cases of anterior shoulder instability were included (78% arthroscopic, 22% open). Clinically significant improvements in PROMs were achieved up to 1 year post-operatively for Rowe, Western Ontario Instability Index (WOSI), American Shoulder and Elbow Surgeons (ASES), and Simple Shoulder Test (SST) scores. For the three most utilized tools (Rowe, WOSI, ASES), the majority of improvement occurred in the first 6 post-operative months. Clinically significant improvements in Constant Score and Oxford Shoulder Instability Score (OSIS) were achieved up to 6 months and 2 years after surgery, respectively. No clinically significant improvements were achieved on the Disabilities of the Arm, Shoulder, and Hand (DASH) tool. Conclusion Maximal medical improvement as determined by commonly utilized PROMs occurs by 1 year after operative management of anterior shoulder instability. The DASH tool does not appear to demonstrate a reliable time frame for clinically significant outcome improvement.
Abstract CT236: A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis
Vilar-Sanchez, Eduardo, Correa, Marcia R. Cruz, Grandval, Philippe , Llor, Xavier , Riegert‐Johnson, Douglas L. , Saurin, Jean‐Christophe , Sussman, Daniel A. , Weinberg, David S. , Attiyeh, Edward F., Joseph, Devanand, Raybold, Kelly, Borzillo, Gary , Smith, Michael , Xie, Hong , Bachman, Kurtis E. , Infante, Jeffrey R., Samadder, N. Jewel , Burke, Carol A. , Dekker, Evelien , Grady, William M. , Katona, Bryson W , Stanich, Peter P. , Prior, Thomas J.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT236-CT236

10.1158/1538-7445.am2020-ct236 Get It

Abstract Background: Familial adenomatous polyposis (FAP) is the most common hereditary polyposis syndrome. It is an autosomal dominant inherited disorder characterized by the early onset of hundreds to thousands of adenomatous polyps throughout the colon. If left untreated, nearly all individuals with this syndrome develop colorectal cancer (CRC) by the third decade of life. Prophylactic colectomy is the standard of care, but individuals remain at risk for malignant transformation of duodenal polyps, rectal polyps for those who have undergone rectal-sparing surgeries, and ileal pouch polyps for those with ileal pouch-anal anastomoses. Multiple studies with both nonselective and selective cyclooxygenase inhibitors (such as sulindac or celecoxib) have shown that anti-inflammatory agents may prevent the formation and inhibit the growth of colorectal adenomatous polyps. However, toxicities associated with these agents and their limited efficacy have prevented their further development. Therefore, there is a high unmet need for novel treatment options to reduce polyp burden, delay or eliminate the need for colectomy and recurrent rectal surgery, and intercept the development of adenocarcinomas in individuals with FAP. Polyps from individuals with FAP display inflammatory features associated with the activation of the IL-23/IL-17/JAK/STAT3 pathway. This inflammation is thought to contribute to further carcinogenesis, culminating in tumor development. Specifically, IL-23 is linked to tumor growth and progression in CRC, and adenomas with high-grade dysplasia showed elevated levels of IL-17A and pSTAT3. Guselkumab, a human monoclonal antibody directed against the p19 subunit of IL-23, specifically targets IL-23 and inhibits its interaction with the IL-23 receptor. Pre-clinical models suggest that inhibition of IL-23 signaling will result in less inflammation and reduce tumor development. Methods: This randomized, blind, placebo-controlled study will evaluate the safety and efficacy of guselkumab in adults with FAP (genetic or clinical diagnosis) who have already undergone colectomy. Polyps with a sum of diameters ≥10 mm in the rectum or pouch are required. Subjects will be randomized equally to one of three study arms: 100 mg, 300 mg, or placebo given subcutaneously every 4 weeks for 6 doses. The primary efficacy endpoint is percentage change from baseline in rectal/pouch polyp burden after 24 weeks. Secondary efficacy endpoints include duodenal polyp burden change and changes in InSiGHT and Spigelman staging. Exploratory translational research objectives will explore changes in RNA expression profiles, epigenomic profiles, cytokine levels, and the microbiome. Exclusion criteria include prior IL-23 targeted therapies and any polyps >1 cm that cannot be removed. While participating, subjects are required to stop any other FAP-directed drug therapy except for aspirin. As of January 2019, 18% of the planned 72 subjects have been enrolled. ClinicalTrials.gov Identifier: NCT03649971. Citation Format: Eduardo Vilar-Sanchez, Carol Burke, Marcia R. Cruz Correa, Evelien Dekker, William M. Grady, Philippe Grandval, Bryson W. Katona, Xavier Llor, Douglas L. Riegert-Johnson, Jean-Christophe Saurin, Peter Stanich, Daniel A. Sussman, David Weinberg, Edward F. Attiyeh, Devanand Joseph, Kelly Raybold, Gary V. Borzillo, Thomas J. Prior, Michael Smith, Hong Xie, Kurtis E. Bachman, Jeffrey R. Infante, Niloy Jewel Samadder. A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT236.
Abstract CT128: IMU-201-101 - an open-label, multi-center, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer
Kaumaya, Pravin, Marino, Mark T. , Ede, Nick, Good, Anthony J., Kaumaya, Pravin T. P. , Bekaii‐Saab, Tanios , Phan, Tri Giang

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT128-CT128

10.1158/1538-7445.am2020-ct128 Get It

Abstract Background: The inhibitory immune pathway, consisting of the receptor programmed cell death 1 (PD-1) and its ligands, PD-L1 and PD-L2, plays a vital role in the maintenance of peripheral tolerance. Therapies with monoclonal antibodies targeting PD-1 and its ligands are associated with remarkable response rates in various cancers. Imugene is proposing to develop an anti-PD-1 immunotherapy using a vaccine approach to treat patients with tumors that over-express PD-L1. The hypothesis is that a polyclonal-induced B-cell antibody response will be more effective or as effective with improved safety over current monoclonal antibody therapy. IMU-201, is a B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T cell epitope (amino acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker (G-P-S-L), combined in an aqueous phase vaccine to be emulsified in Montanide ISA 720 VG, to form the drug product. Study Design: IMU-201-101 is a 2-part open-label dose escalation/dose expansion study of IMU-201. Part 1 will dose escalate IMU-201 as monotherapy and in combination with Standard of Care (SOC) treatment to evaluate safety, tolerability and immunogenicity and assess the optimal biologic dose (OBD) of IMU-201. Part 2 will expand the number treated with IMU-201 at OBD in combination with SOC treatment. OBD is defined as the dose resulting in the best safety/tolerability and immunogenicity and will be determined after all dose cohorts have completed Day 29 of Part 1. A total of approximately 30 adult patients aged 18 years with NSCLC expressing PD-L1 will be enrolled in the study at sites in North America and Australia. In Part 1, three cohorts (25, 125 and 250 µg of IMU-201) of 3-6 participants per cohort are anticipated to establish the Optimum Biological Dose (OBD) of IMU-201 as monotherapy (mOBD). After establishing mOBD, combination dose escalation will combine IMU-201 with SOC treatment which may include ICI, chemotherapy or their combination, to establish combination OBD (cOBD). The starting dose for combination dose escalation will be one dose level below mOBD. The same dosing schedule of IMU-201, DLT criteria, and dose escalation rules will be used to establish mOBD and cOBD. In Part 2, the number of patients treated in combination with IMU-201 at cOBD will be expanded to 12 patients. Patients will receive IMU-201 at Baseline/Day 1, Day 15 and Day 29. Dosing with IMU-201 will continue at Day 64 (± 7 days) and every subsequent 63 days (± 7 days) until progressive disease or complete response. Therapy may continue beyond progression if the treating physician feels that the patient is deriving benefit. Primary Objectives: To evaluate the safety/tolerability and immunogenicity of IMU-201 as monotherapy and in combination with SOC treatment. To identify OBD of IMU-201 as monotherapy and in combination with SOC treatment. To evaluate changes in immunological, biochemical and additional radiological markers of tumor progression in patients treated with IMU-201 as monotherapy and in combination with SOC treatment. To evaluate changes in humoral and cellular immunogenicity data including PD-1 specific antibodies (IgG, IgM), vaccine-specific cytokine levels and regulatory and effector T and B cells. Citation Format: Pravin Kaumaya, Tanios Bekaii-Saab, Tri Phan, Mark T. Marino, Nick Ede, Anthony Good. IMU-201-101 - an open-label, multi-center, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT128.
Top Ten Tips Palliative Care Clinicians Should Know About Interventional Pain and Procedures
Chou, Claudia , Hopkins, Thomas J. , Badiola, Ignacio , Gohil, Sharmil, Kitt, Arthur, Luke, Whitney, Vaughan, Christina , Jones, Christopher A. , Varhabhatla, Narayana, Chou, Claudia Z., Gazelka, Halena M. , Jones, C. P.

Mayo Clinic

Journal of Palliative Medicine | August 31, 2020 | Volume: 23 | Issue: 10 | Pages: 1386-1391

10.1089/jpm.2020.0487 | PMID 32865443 Get It

Pain is a common symptom for patients with advanced illness. Palliative care (PC) clinicians are experts in pharmacologic and nonpharmacologic treatment of pain and other symptoms for these patients. True multimodal pain control should include consideration of interventional procedures and pumps to improve difficult-to-manage pain. This article, written by clinicians with expertise in interventional pain and PC, outlines and explains many of the adjunctive and interventional therapies that can be considered for patients with pain in the setting of serious illness. Only by understanding and considering all available options can we ensure that our patients are receiving optimal care.
Connecting community‐delivered evidence‐based programs and the healthcare system: Piloting a learning “wellcare” system
Redmond, Sarah , Leppin, Aaron L. , Hanson, Gregory J. , Minteer, Sarah A. , Fischer, Karen, Hanson, Gregory, Doubeni, Chyke, Takahashi, Paul, Fischer, Karen M. , Hanson, Gregory, Doubeni, Chyke A. , Takahashi, Paul Y.

Mayo Clinic

Learning Health Systems | August 28, 2020 | Volume: 5 | Issue: 4 | Pages: No page available

10.1002/lrh2.10240 | PMID 34667870 Get It

AbstractIntroductionMany evidence‐based programs (EBPs) have been determined in randomized controlled trials to be effective, but few studies explore the real‐world effectiveness of EBPs implemented in the natural community setting. Our study evaluated whether a novel linked infrastructure would enable such insights and continuous improvement as part of a learning healthcare‐community bridged “wellcare” ecosystem.MethodsWe created a secure, web‐based data entry and storage platform with a network of Minnesota community‐based organizations to record EBP participants' demographics and attendance, and program details. We then linked participant's information to their Rochester Epidemiology Project (REP) medical records. With this infrastructure, we conducted a proof of concept, retrospective cohort study by matching EBP participants to REP controls and comparing medical record‐documented outcomes over 1 year follow‐up.ResultsWe successfully linked EBP participant records with medical records in 77.6% of cases, and the infrastructure proved feasible and scalable. Still, key challenges remain in obtaining participant consent for data sharing. Upfront resource investments and the availability of REP‐like warehouses limit generalizability. Optimal learning will be improved by enhancements that better track program fidelity. Our pilot study established a proof‐of‐concept, but sample sizes (n = 99 for falls prevention and n = 97 chronic disease/pain management EBP completers) were too small to detect significant differences in hospital admittance as compared to matched controls for either EBP group, (OR = 0.66[0.36, 1.19]) and (OR = 0.81[0.43, 1.54]), respectively. Events were too rare to gather meaningful information about effects on fall rates.ConclusionsOur pilot demonstrates the feasibility of developing an online infrastructure that connects information from community leaders with medical record documented health outcomes, bridging the knowledge gap between community programs and the health care system. Insights gleaned from our infrastructure can be used to continuously shape community program delivery to reduce the need for formal health care services.